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Purpose: Acinetobacter was known as a saprophytic colonizer, 
yet it is considered an important etiologic agent which is isolated 
from hospital-acquired infections. In this study, we aimed to 
investigate fatality rates, factors for fatality of Acinetobacter 
infections and relationship between combination therapies and 
survival.  
Patients and Methods: We evaluated patients with 
Acinetobacter infection in ICU for demographic and clinical 
characteristics, combination therapies and adverse effects of 
these therapeutic options, retrospectively.  
Results: Ninety-one patients with proved Acinetobacter 
infection were included in this study. We found that the fatality 
rate of Acinetobacter infection in ICU was 56%. Advanced age  
was significantly related with fatality.  We found that 
carbapenem resistance increased steadily during a 5 year period, 
fatality rates significantly decreased with combination therapies 
including aminoglycosides. There wasn’t significant relation 
between colistin therapy and survival in patients with 
Acinetobacter infections. 
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Acinetobacter species is considered as pathogens with low virulence. 
Immunocompetent individuals do not develop disease easily. They usually cause 
hospital-acquired infections. The risk of infection with Acinetobacter species has 
increased in ICUs especially in patients, who need mechanical ventilation, lost 
his/her skin integrity due to a trauma or burn, has immunosuppression, was 
implanted with central venous catheter, has recently undergone a surgical 
operation, used fluoroquinolone, 3. generation cephalosporin and carbapenem and 
has enteral nutrition regime.(1) Acinetobacter infections have become more 
frequent and more serious problems in the daily medical practice of the infection 
diseases physicians upon increasing older population, use of new and stronger 
antibiotics, increase and diversification of interventional operations, and 
development of ICUs.This importance may attributed to its pan-resistance to 
antibiotics, survival in many environmental surfaces, ability to cause epidemics in 
the unit and severe morbidity, fatality and economic costs.(2, 3) 
Guidelines have been developed by ECDC (European Centre for Disease 
Prevention and Control) and CDC (Centers for Disease Control and Prevention) 
joint venture to determine the antibiotic resistance characteristics of 
Acinetobacter species.(4) There are identified risk factors for colonization and 
infection with resistant microorganisms in the intensive care units.(5-7) First 
therapy option in infections with sensitive Acinetobacter strain is a monotherapy 
with the broad-spectrum cephalosporins (ceftazidime or cefepime), beta-
lactam/beta lactamase combinations containing sulbactam or carbapenems 
(meropenem, imipenem or doripenem). However, it has been reported that 
resistance developed with monotherapy.(8, 9) Therefore, a combined therapy with 
an anti-pseudomonal fluoroquinolone or an aminoglycoside can be administered. 
Administration of polymyxin E (colistin) and tigecycline may be considered as an 
alternative treatment of multidrug resistant Acinetobacter infections. (10) 
In this study, we aimed at investigating the demographic, epidemiologic and 
survival data of the hospital-acquired infections caused by Acinetobacterspecies in 




Conclusion: Critically ill patients with advanced age should be 
assessed thoroughly for Acinetobacter infection and prior 
carbapenem use. The empirical antibiotic treatment started 
earlier based on such risk factors may decrease fatality. The 
antimicrobial combinations including aminoglycoside may be 
considered more in order to the local resistance data. 
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Patients and Methods 
 
Istanbul Sisli Hamidiye Etfal Training and Research Hospital is a training 
and research hospital with 900 beds. There are 3 intensive care units with 20 beds 
in total at our hospital. This study included patients, who admitted to the 
intensive care units between January 2008 and June 2013 and stayed for at least 
48 hours in ICU, and was found Acinetobacter spp. in the culture reports 
obtained microbiology laboratory. The demographic data of these patients and 
their intubation and mechanical ventilation need during admission to ICU, 
presence of central venous catheter, recent application of surgical intervention, 
trauma, malignity, APACHE II score during admission and antibiotic treatments 
were recorded retrospectively from the computer system of the hospital. 
Acinetobacter infection was assessed according to specific criteria (CDC). 
Tracheal aspirate and urine cultures were performed quantitatively and catheter 
tip cultures were performed semi-quantitatively. According to CDC criteria(11) 
66 patients, who did not have Acinetobacter infection criteria (12/66) and whose 
records could not be obtained (54/66) were excluded from the study. 
Regression of infection findings was determined as the primary outcome, 
while fatality associated with Acinetobacter infection was determined as the 
secondary outcome. Fatality associated with Acinetobacter infection was assessed 
as the fatality up to day30th following Acinetobacter growth in the culture. 
Creatinine values and Modification of Diet in Renal Disease (MDRD) 
equation(12) as well as renal functions from the initiation date of antibiotic 
treatment due to Acinetobacter infection was assessed in all patients administered 
with colistin. RIFLE (Risk, Injury, Failure, Loss, End Stage Kidney Disease) 
criteria, which were proven to be suitable for assessing renal functions with use of 
colistin(13-15), was used for identifying renal failure. 
The microorganisms were defined as carbapenem resistant if Acinetobacter 
spp with zone diameter ≤ 13 mm for both imipenem and meropenem were 
recorded. Furthermore, carbapenem resistance was also assessed by Etest® 
(BioMerieux, USA) according to MIC.Antibiotic susceptibility was determined by 
the disc diffusion method and MIC values according to the guidelines of the 
Clinical and Laboratory Standards Institute (CLSI).(16) 
Local ethic committee approval was obtained at May 2013. 
 
Statistical Methods 
Computer software (STATA v.12, StataCorp, Texas, USA) was used for 
statistical assessments.  Data were reported as mean ± SD. Student t test, 
matched t test, χ2 test, Mann Whitney U and Wilcoxon tests were used to 
univariate analysis. In univariate analysis two-tailed P value smaller than or 
equal 0.05 was used statistical significance level. Dependent variables were 
assessed using multi-variable logistic regression analysis.  Kaplan-Meier graphic 
was used for survival analysis.  
 
Results 
The medical records of 157 patients, who were admitted to the intensive care 
units between January 2008 and June 2013 and determined to have Acinetobacter 
infection were assessed retrospectively. Ninety-one patients were included in the 
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study. The fatality rate of a total of 887 patients admitted to the intensive care 
units during the study period was 70%. In 91 patients included in the study, all-
cause fatality rate was found to be 65% (n=60), while the fatality rate attributed 
to the Acinetobacter infections validated with the culture after occurrence of the 
systemic infection results was found to be 56% (n=51).  
 The demographical and clinical data of the patients as well as the risk 
factors determined for Acinetobacter infection in the literature were summarized 
in Table I. 
 
Table I Demographical and Clinical Data and Risk Factors in 
Critically İll Patients with Acinetobacter Infection 
Demographical Data  
• Number of patients 91 
• Age (Year) 59 ±18  
• Gender (M/F) 42/39 
Clinical Data  
• APACHE II  16±6  
• Duration of Hospitalization (day) 74±59 
• Mechanical Ventilation 86 
• Orotracheal Intubation 46% (42) 
• Tracheostomy 48% (44) 
Risk Factors  
• Recent surgical intervention 80% (73) 
o Brain Surgery 51% (47) 
o Others 29% (26) 
• Neurological disease 41% (37) 
• Trauma 29%(26) 
• Malignity 25% (23) 
• Diabetes Mellitus 18% (16) 
• Cardiovascular disease 40% (36) 
 
 
Clinical diagnosis in order to Acinetobacter infection site, simultaneous 
Acinetobacter bacteremia and average death days of the patients and fatality rate 
attributed to Acinetobacter Infection are summarized in table II. 
 
Table II Clinical diagnosis, blood culture positivity and average mortality days 






VAP/NP 54% (49) 65% (32) 13±7 67% 
Meningitis 11% (10) 70%(7) 10±5 30% 
SV Catheter infection 10% (9) 78% (7) 12±2 22% 
Primary Bloodstream Infection 10% (9) 100% (9) 18±9 N/A 
Soft Tissue Infection 6% (5) 20% (1) 20±9 N/A 
Intraabdominal Infection 6% (5) 20% (1) 21±8 N/A 
Urinary System Infection 4% (4) 50% (2) 18±9 N/A 
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Acinetobacter baumannii- calcoaceticus grown in the blood cultures of 59 
(65%) out of ninety one patients, which were taken during systemic infection 
attack. There was no other systemic infection focus accompanying 9 (15%) of 
fifty nine bacteremia attacks and it was determined to be primary bloodstream 
infection. Of fifty nine bacteremia attacks, 32 (54%) were accompanied with 
VAP/HAP and 7 (11%) were accompanied by CV catheter infections, which were 
other Acinetobacter infections.  
Eighty-four (92%) of the isolated strains were resistant to carbapenem. While 
the resistance to carbapenem was 84% in 2008, it was found to be 100% in 2012 
(p<0.05). In 84 patients isolated with Carbapenem-resistant Acinetobacter 
baumannii- calcoaceticus, the number of patients receiving carbapenem during 
the last 3 months was 51 (61%), which is significantly higher (p=0.01) than 
patients which had no carbapenem history or was received at least 3 months 
before admission . All-infection fatality caused by infections of carbapenem- 
resistant species of Acinetobacter was found to be significantly higher (p<0.05). 
We couldn’t evaluate resistance trend to colistin, because it was not in the 
market before 2011. No resistant origin was found since 2011, when the resistance 
to colistin was started to be investigated routinely. 
Fatality was found to be 13 ±7 days in the VAP/HAP cases associated with 
Acinetobacter. Fatality rate was found 67% in the VAP/HAP attacks. The 
association between recent surgical intervention and other chronic diseases and 
fatality was not found to be significant in a single-variable analysis. While no 
statistical significance was determined in the multi-variable analysis model, it was 
found that Acinetobacter VAP/HAP fatality was 3 times higher in patients with 
malignity (p=0.07).  Advanced age was found to be most important factor 
attributed to fatality of Acinetobacter infections. 
A total of 10 Acinetobacter meningitis cases were included in the study. All 
Acinetobacter meningitis cases were associated with the recent brain surgery 
intervention. Eight (80%) of the isolated strains were resistant to carbapenem. 
Two (20%) of the patients with meningitis had bacteremia. Four of the cases had 
undergone operation due to a mass in MSS. Others had undergone brain surgery 
due to cerebrovascular diseases. Fatality associated with Acinetobacter meningitis 
was found to be 30% (n=3) in the patients included in our study.  
Seven (78%) of nine central venous (CV) catheter infection attacks had 
accompanying bacteremia. Fatality was assessed as 22% (n=2) in CV catheter 
infections.   
Colistin was used in treatment of all 36 patients. Acute renal failure 
associated with use of colistin was determined in 16 (44%) patients.  The loading 
dose and high dose colistin (450 mg) were administered to 8 of 36 patients. Upon 
administration of two different doses of colistin, the fatality rate was found to be 
64% in case of administration of low dose without loading, while it was found to 
be 50% in case of administration loading dose followed by a higher-dose 
maintenance treatment. No significant difference was found between the 
administration of low dose without loading dose and the loading dose followed by 
high dose of colistin in terms of renal failure. Mean duration of use of colistin in 
the group which developed renal failure, was 15±9 days, while it was 6±2 days in 
the group which did not develop renal failure. Such difference was not found to 
be statistically significant. 
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When 59 patients with growth in blood culture were assessed, no significant 
relationship with fatality associated with Acinetobacter was found. Average 
duration of stay at the ICU was 81±51 days in patients with Acinetobacter 
growth in blood culture, while it was 51±39 days in patients without 
Acinetobacter growth in blood culture. This difference was found to be 
statistically significant (p<0.05). 
In a multi-variable analysis conducted to assess all risk factors and the 
fatality attributed to Acinetobacter, the mean age was found to be 64±16 in the 
fatality group and 53±19 in the survival group (OR:1.06, 95 %CI: 1.02-1.10, 
p=0.002). The analysis results were summarized in table III. 
 







Age 1.06 1.02 - 1.10 0.002 
APACHE2 0.98 0.90-1.08 0.8 
Trauma 0.38 0.13 - 1.12 0.08  
Chronic Kidney Disease 4.61 0.74 - 28 0.10 
 
The combined antibiotic treatments used during the study period are given in 
table IV. 
 
Table IV Antibiotic combinations used in treatment 
 n VAP Other than VAP 
CP + CSB 9 4 5 
CP+AG 12 6 6 
AG+CSB 9 4 5 
COL+TGC 12 6 6 
COL+CP 12 3 9 
COL+CSB 10 6 4 
TGC+AG 10 7 3 
CP+TGC 10 7 3 
 CP: Carbapenems CSB: Cefoperazone-Sulbactam AG: Aminoglicoside COL: Colistin TGC: Tigecycline 
 
The relationship between the combined treatments used in all types of 
carbapenem resistant Acinetobacter infections and the survival rate was 
compared using regression analysis. It was found that the treatment, which was 
significantly effective on survival, was a combination of Cefoperazone-Sulbactam 
and one aminoglycoside (netilmicin in 20 patients and amikacin in 19 patients) 
(p=0.03). Whether each drug was studied alone, it was found that use of 
aminoglycoside was positively effective on survival (Fig 1). There was no 
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Acinetobacter species may cause suppurative infections on each organ and 
system.(17) Among Acinetobacter species, the most important one that is 
responsible for infections at ICUs is A. baumannii. The most commonly observed 
pathology is ventilator associated pneumonia and primary bloodstream infection. 
According to a report published by USA National Health Services Security 
Network (NHSN) in 2008, of Acinetobacter isolates, 8.4% is responsible for VAP, 
2.2% is responsible for primary bloodstream infection, 1.2% is responsible for 
urinary system infection associated with catheter and 0.6% is responsible for 
infection at surgical area.(18) The crude mortality rate of Acinetobacter 
infections varies between 26% and 68%.(19) In a review published by Falagas et 
al in 2006, it was reported that the fatality rates attributed to Acinetobacter 
infections in the intensive care units ranged between 10% and 43%.(20) 
Acinetobacter spp. currently appears as a causative agent of hospital-acquired 
infection - especially in ICUs - and causes the most common hospital-acquired 
pneumonia. Most of the hospital-acquired pneumonia are observed in the patient 
group, who receive mechanical ventilation.(21) In our study respiratory system 
involvement was most frequent Acinetobacter infection. This finding is in 
compliance with the literature data. According to our findings, the second most 
common infection type was meningitis. In many publications, it was reported that 
the meningitis cases caused by Acinetobacter species were observed less 
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commonly.(22) This may be explained by frequent intracranial mass and 
arteriovenous malformation operations performed in our hospital and the fact 
such patients stay together with the other intensive care patients, when they 
require intensive care. The rate of meningitis associated with Acinetobacter 
species can be decreased by checking the information and compliance of the 
personnel about application and maintenance of catheters and their compliance to 
the infection control measures.  
The fatality rate attributed to the hospital-acquired infections caused by 
Acinetobacter species varies between 7% and 43%.(20, 23) Such data vary based 
on the characteristics of the clinic, where the patient stays, or place of 
involvement. Severe disease, old age, inappropriate antimicrobial treatment, 
bacteremia associated with pneumonia, increased serum creatinine, presence of 
malignity, mechanical ventilation and resistance to carbapenem.(24) Such risk 
factors for fatality were assessed in our study. The all-cause fatality rate in the 
patients admitted to the intensive care unit during the study period was found to 
be 70% and, when 91 Acinetobacter infection attacks during this period were 
considered, the fatality rate attributed to Acinetobacter infections was found to 
be 56%. The independent risk factor statistically significant with the fatality 
included old age. In addition, isolation of Acinetobacter species from respiratory 
secretions was determined to be a factor increasing the fatality significantly. 
APACHE2 mean of the included patients was found to be 16±5. We cannot find 
correlation between APACHE 2 score and fatality. 
The recommended dose of colistin, which has been widely available during 
the last 6 months of 2010 in Turkey, was 2.5-5 mg/kg (mean 300 mg/day) 
according to the guidelines. From 2012, administration of the loading dose (300 
mg) and higher dose in maintenance (450 mg/day)(25, 26) has become more 
common. In a meta-analysis, it was shown that intravenous colistin did not cause 
more nephrotoxicity compared to the other antibiotics.(10, 27) And in our 
hospital, the doses administered until the first 6 months of 2012 was 2.5-5 mg/kg 
(n=28) followed by the loading dose and higher doses in maintenance (n=8) 
according to the guidelines.  Colistin was administered in combination with 
cefoperazone-sulbactam, carbapenem (imipenem or meropenem) or tigecycline. In 
case of carbapenem-resistant Acinetobacter infections, the combination 
treatments with colistin did not show a significant decrease in the fatality 
compared to the other treatments.  An increase was observed in the acute renal 
failure upon administration of colistin, but it was not significant. No increase was 
observed in the acute renal failure upon administration of high dose of colistin. 
Further studies are required to assess the impact of the treatment on fatality and 
nephrotoxicity. 
As alternative drug, aminoglycosides are recommended for carbapenem 
resistant Acinetobacter infections in combinations.(22) Use of aminoglycosides in 
the combination treatment (netilmicin or amikacin) in our study was found to be 
associated with low fatality in the patients infected with carbapenem resistant 
Acinetobacter infections. Nowadays, resistance to antibiotics has increased from 
day to day with decreasing number of treatment options, we can recommend 
more rational use of aminoglycosides in treatment methods in case of carbapenem 
resistant Acinetobacter infections.  Further studies are required to validate this 
situation. 
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In conclusion, critically ill patients with advanced age should be assessed 
thoroughly for Acinetobacter infection and prior carbapenem use. The empirical 
antibiotic treatment started earlier based on such risk factors may decrease 
fatality. The antimicrobial combinations including aminoglycoside may be 
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